Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) duling repeated or continuous intravenous infusion of heparin in man

Thrombosis and Haemostasis

Volumn 76, Issue 5, 1996, Pages 703-709

  Hansen, John Bjarne ^a   Sandset, Per Morten ^b   Huseby, Kirsten Raanaas ^a   Huseby, Nils Erik ^a   Nordøy, Arne ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME;

EID: 0029954939     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650647     Document Type: Article

References (48)

1. Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a "prima ballerina". Thromb Haemost 1995; 74: 7-17.
2. Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
3. Broze Jr. GJ, Miletich JP. Characterizations of the inhibition of tissue factor in serum. Blood 1987; 69: 150-5.
4. Rao LVM, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987; 69: 645-51.
5. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ. Functional significance of the Kunitz-type inhibitor domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
6. Abumiya T, Enjyoji K, Kokawa T, Kamikubo Y, Kato H. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. J Biochem 1995; 118: 178-82.
7. Norfang O, Bjørn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 1991; 30: 10371-6.
8. Wesselschmidt R, Likert KM, Girard TJ, Wun TC, Broze Jr. GJ. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992; 79: 2004-10.
9. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-73.
10. Sandset PM, Abildgaard U. Extrinsic coagulation inhibitor: the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21: 219-39.
11. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
12. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordøy A. Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 1994; 14: 223-9.
13. Hull RD, Raskob GE, Hirsch J, Jay RM, Ledere JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L, Gent M. Continous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-14.
14. Neri Serneri GG, Gensini GF, Poggesi L, Trotta F, Modesti PA, Boddi M, Ieri A, Margheri M, Casolo GC, Bini M, Rostagno C, Carnovali M, Abbate R. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischemia in refractory unstable angina. Lancet 1990; 335: 615-8.
15. Bourin MC, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 1993; 289: 313-30.
16. Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost 1995; 74: 1209-14.
17. Nordøy A. Difference in the heparin-neutralizing effect of protamine and polybrene as tested by thrombotest. Scand J Clin Lab Invest 1963; 15: 205-10.
18. Lindahl AK, Abildgaard U, Larsen ML, Staalesen R, Hammer AKG, Sandset PM, Norfang O, Beck TC. Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Thromb Res 1991; 62: 607-14.
19. Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hansen TA, Nordøy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anti-coagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb Vasc Biol 1995; 15: 879-85.
20. Novotny WF, Palmier M, Wun TC, Broze GJ, Miletich JP. Purification and properties of heparin releasable lipoprotein-associated coagulation inhibitor. Blood 1991; 78: 394-400.
21. Lindahl AK, Abildgaard U, Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991; 64: 155-68.
22. Harenberg J, Siegele M, Dempfle CE, Stehle G, Heene DL. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins. Thromb Haemost 1993; 70: 942-5.
23. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992; 3: 439-49.
24. Huseby KR, Hansen JB, Huseby NE, Nordøy A. The anticoagulant potential of tissue factor pathway inhibitor (TFPI) is restricted to its free form in human plasma. Thromb Haemost 1995; 73: 1260 (abstract).
25. Valentin S, Østergaard P, Kristensen H, Norfang O. Synergism between full length TFPI and heparin: evidence for TFPI as and important factor for the antithrombotic activity of heparin. Blood Coagul Fibrinolysis 1992; 3: 221-2.
26. Anderson S, Cohen AT, Melissari E, Scully MS, Kakkar VV. Loss of heparin-releasable tissue factor pathway inhibitor in patients undergoing PTCA. Thromb Haemost 1995; 73: 328-9.
27. Erhardsen E, Ezban, Madsen MT, Diness V, Glazer S, Hedner U, Norfang O. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 1995; 5: 388-95.
28. Kasper CK, Aledort ML, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eys J. A more uniform measurement of factor VIII inhibitors. Thrombos Diathes haemorrh 1975; 34: 869-72.
29. Hjort PF. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand J Clin Lab Invest 1957; 9 (suppl 27): 1-173.
30. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Ødegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis 1991; 2: 425-33.
31. SAS Institute Inc, SAS/STAT Guide for personal computers, version 6. Cary, NC: SAS Institute 1987.
32. Ariens RAS, Faioni EM, Mannucci PM. Repeated release of the tissue factor pathway inhibitor. Thromb Haemost 1994; 72: 327-8.
33. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-93.
34. Warn-Cramer BJ, Maki SL, Zivelin A, Rapaport SI. Partial purification and characterization of extrinsic pathway inhibitor (the factor Xa-dependent plasma inhibitor of factor VIIa/tissue factor). Thromb Res 1987; 48; 11-22.
35. Hubbard AR, Jennings CA. Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins. Thromb Res 1987; 46: 527-37.
36. Iversen N, Sandset PM, Abildgaard U, Rao LVM, Nordfang O. Binding of recombinant tissue factor pathway inhibitor (rTFPI) to endothelial cells: Influence of glucosaminoglycans. Thromb Haemost 1993; 69: 368 (abstract).
37. Petersen JGL, Meyn G, Rasmussen JS, Christiansen L, Petersen J, Bjørn SE, Jonassen I, Norfang O. Characterization of human tissue factor pathway inhibitor (TFPI) variants expressed in saccharomyces cerevisae. J Biol Chem 1993; 268: 13344-51.
38. Wesselschmidt R, Likert K, Huang Z, Broze Jr. GJ. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 1993; 4: 661-9.
39. Valentin S, Larnkjær A, Østergaard P, Nielsen JI, Norfang O. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994; 75: 173-83.
40. Valentin S, Norfang O, Bregengard C, Wildgoose P. Evidence that the C-terminus for tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul Fibrinolysis 1993; 4: 713-20.
41. Palmier MO, Hall LJ, Reisch CM, Baldwin MK, Wilson AG, Wun TC. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost 1992; 68: 33-6.
42. Bregengaard C, Norfang O, Østergaard P, Petersen JGL, Meyn G, Diness V, Svendsen O, Hedner U. Pharmakokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemost 1993; 70: 454-7.
43. Warshawsky I, Broze Jr. GJ, Schwartz AL, The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 6664-8.
44. Warshawsky I, Bu G, Mast A, Saffitz JE, Broze Jr. GJ, Schwartz AL. The carboxy-terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995; 95: 1773-81.
45. Almus FE, Rao LVM, Rapaport SI. Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arterioscler Thromb 1993; 13: 105-11.
46. Grabowski EF, Zuckerman DB, Nemerson Y. The functional expression of tissue factor by fibroblasts and endothelial cells under flow conditions. Blood 1993; 81: 3265-70.
47. Sandset PM, Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiological role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991; 88: 70812.
48. Hommes DW, Bara A, Mazzolai L, Büller HR, ten Cate JW. Subcutaneous treatment compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Int Med 1992; 116: 279-84.